Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-08-27
2009-06-02
Aulakh, Charanjit S (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S040000, C544S233000, C514S248000
Reexamination Certificate
active
07541364
ABSTRACT:
Compounds represented by the formula:wherein R is C1-6alkyl; C4-6cycloalkylalkyl; or C3-6alkenyl; R′ is H or C1-6alkyl; X is H or OH; Y is alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl or aroyl; and Z is CH or N; provided that X is H, when Z is CH and R is C4cycloalkylalkyl or C4alkenyl; prodrugs thereof; and pharmaceutically acceptable salts thereof are provided. Compounds of the above formula are useful as analgesics for treating pain; as immunomodulators, to modulate the behavioral effects of drugs of abuse and to modulate the development of tolerance and dependence to μ agonists.
REFERENCES:
patent: 6465479 (2002-10-01), Ananthan
patent: 7015326 (2006-03-01), Ananthan
patent: 7105675 (2006-09-01), Ananthan
patent: 2006/0264452 (2006-11-01), Ananthan
patent: WO 2006130471 (2006-12-01), None
Ullrich, T. et al.: derivatives of the 17-(2-methylallyl)-substituted noroxymorphone: Variation of the delta address and its effects on affinity and selectivity for the delta opioid receptor. Bioorg. & med. Chem. Lett., vol. 11, pp. 2883-2885, 2001.
“Synthesis, Opioid Receptor Binding, and Bioassay of Naltrindole Analogues Substituted in the Indolic Benzene Moiety”; Subramaniam Ananthan et al.; J. Med. Chem. 1998, 41, 2872-2881.
“Synthesis, Opioid Receptor Binding, and Biological Activities of Naltrexone-Derived Pyrido- and Pyrimidomorphinans”; Subramaniam Ananthan et al.; J. Med. Chem. 1999, 42, 3527-3538.
“Synthesis, Opioid Receptor Binding, and Functional Activity of 5′-Substituted 17-Cyclopropylmethylpyrido[2′,3′:6,7]morphinans”; Subramaniam Ananthan et al.; Science Direct, Bioorganic & Medicinal Chemistry Letters 13 (2003) 529-532.
“Novel Ligands for the Opioid Receptors: Synthesis and Structure-Activity Relationships among 5′-Aryl and 5′Heteroaryl 17-Cyclopropylmethyl-4,5 α-epoxypyrido[2′,3′:6,7]morphinans”; Subramaniam Ananthan et al.; Science Direct, Bioorganic & Medicinal Chemistry 11 (2003) 4143-4154.
“Identification of Opioid Ligands Processing Mixed μ Agonist/δ Antagonist Activity among Pyridomorphinans Derived from Naloxone, Oxymorphone, and Hydropmorphone”; Subramaniam Ananthan et al.; J. Med. Chem. 2004, 47, 1400-1412.
Calcagnetti, D. J.; Keck, B. J.; Quatrella, L. A.; Schechter, M. D. Blockade of cocaine-induced conditioned place preference; relevance to cocaine abuse therapeutics.Life sciences1995, 56, 475-483.
Coop, A.; Rice, K. C. Role of delta-opioid receptors in biological processes.Drug news&perspectives2000, 13, 481-487.
Heidbreder, C.; Goldberg, S. R.; Shippenberg, T. S. Inhibition of cocaine-induced sensitization by the delta-opiod receptor antagonist naltrindole.European journal of pharmacology1993, 243, 123-127.
Heidbreder, C.; Shoaib, M.; Shippenberg, T. S. Differential role of delta-opioid receptors in the development and expression of behavioral sensitization to cocaine.European journal of pharmacology1996, 298, 207-216.
Menkens, K.; Bilsky, E. J.; Wild, K. D.; Portoghese, P. S.; Reid, L. D.; Porreca, F. Cocaine place preference is blocked by the delta-opioid receptor antagonist, naltrindole.European journal of pharmacology1992, 219, 345-346.
Reid, L.D.; Glick, S. D.; Menkens, K. A.; French, E. D.; Bilsky, E. J.; Porreca, F. Cocaine self-administration and naltrindole, a delta-selective opioid antagonist.Neuroreport1995, 6, 1409-1412.
Reid, L.D.; Hubbell, C. L.; Glaccum, M. B.; Bilsky, E. J.; Portoghese, P. S.; Porreca, F. Naltrindole, an opioid delta receptor antagonist, blocks cocaine-induced facilitation of responding for rewarding brain stimulation.Life sciences1993, 52, PL67-71.
Shippenberg, T. S.; Heidbreder, C. The delta-opioid receptor antagonist naltrindole prevents sensitization to the conditioned rewarding effects of cocaine.European journal of pharmacology1995, 280, 55-61.
Suzuki, T.; Mori, T.; Funada, M.; Misawa, M.; Nagase, H. Attenuation of the discriminative stimulus properties of cocaine by delta-opioid receptor antagonists.European journal of pharmacology1994, 263, 207-211.
Suzuki, T.; Mori, T.; Tsuji, M.; Misawa, M.; Nagase, H. The role of delta-opioid receptor subtypes in cocaine- and methamphetamine-induced place preferences.Life sciences1994, 55, PL339-344.
Froehlich, J. C.; Badia-Elder, N. E.; Zink, R. W.; McCullough, D. E.; Portoghese, P. S. Contribution of the opioid system to alcohol aversion and alcohol drinking behavior.The Journal of pharmacology and experimental therapeutics1998, 287, 284-292.
Krishnan-Sarin, S.; Jing, S. L.; Kurtz, D. L.; Zweifel, M.; Portoghese, P.S.; Li, T. K.; Froehlich, J. C. The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference.Psychopharmacology1995, 120, 177-185.
Krishnan-Sarin, S.; Portoghese, P.S.; Li, T. K.; Froehlich, J. C. The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference.Pharmacology, biochemistry, and behavior1995, 52, 153-159.
June, H. L.; McCane, S. R.; Zink, R. W.; Portoghese, P. S.; Li, T. K.; Froehlich, J. C. The delta 2-opioid receptor antagonist naltriben reduces motivated responding for ethanol.Psychopharmacology1999, 147, 81-89.
Abdelhamid, E. E.; Sultana, M.; Portoghese, P. S.; Takemori, A. E. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice.The Journal of pharmacology and experimental therapeutics1991, 258, 299-303.
Hepburn, M. J.; Little, P. J.; Gingras, J.; Kuhn, C. M. Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats.The Journal of pharmacology and experimental therapeutics1997, 281, 1350-1356.
Suzuki, T.; Tsuji, M.; Mori, T.; Misawa, M.; Nagase, H. Involvement of delta 1 and delta 2 opioid receptor subtypes in the development of phsyical dependence on morphine in mice.Pharmacology, biochemistry, and behavior1997, 57, 293-299.
Arakawa, K.; Akami, T.; Okamoto, M.; Akioka, K.; Nakai, I.; Oka, T.; Nagase, H. Immunosuppression by delta opioid receptor antagonist.Transplantation proceedings1993, 25, 738-740.
Arakawa, K.; Akami, T.; Okamoto, M.; Oka, T.; Nagase, H.; Matsumoto, S. The immunosuppressive effect of delta-opioid receptor antagonist on rat renal allograft survival.Transplantation1992, 53, 951-953.
Carr, D. J.; Radulescu, R. T.; deCosta, B. R.; Rice, K. C.; Blalock, J. E. Differential effect of opioids on immunoglobulin production by lymphocytes isolated from Peyer's patches and spleen.Life sciences1990, 47, 1059-1069.
House, R. V.; Thomas, P. T.; Kozak, J. T.; Bhargava, H. N. Suppression of immune function by non-peptidic delta opioid receptor antagonists.Neuroscience letters1995, 198, 119-122.
Linner, K. M.; Stickney, B. J.; Quist, H. E.; Sharp, B. M.; Portoghese, P. S. The delta1-opioid receptor antagonist, 7-(benzospiroindanyl)naltrexone [correction of 7-benzylspiroindanylnaltrexone], prolongs renal allograft survival in a rat model.European journal of pharmacology1998, 354, R3-5.
Ananthan Subramaniam
Bilsky Edward J.
Porreca Frank
Rothman Richard B.
Amernick Burton A.
Aulakh Charanjit S
Connolly Bove & Lodge & Hutz LLP
Southern Research Institute
LandOfFree
Pyridomorphinans, pyridazinomorphinans and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridomorphinans, pyridazinomorphinans and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridomorphinans, pyridazinomorphinans and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4145607